CGON - CIK 0001991792
The table below shows CG Oncology, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$56.94M | -$29.28M | -$26.01M | -$7.99M |
| Capital expenditure | $304.00K | $16.00K | $12.00K | - |
| Investing cash flow | -$334.85M | -$186.77M | -$307.44M | -$78.70M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $393.00M |
CG Oncology, Inc. reported operating cash flow of -$132.35M for fiscal year 2025. That is down 68.1% from -$78.71M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $450.00K |
| $402.66M |
| -$765.00K |